Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Dong, Peixin ^a   Xu, Zhujie ^b   Jia, Nan ^c   Li, Dajin ^a   Feng, Youji ^a  

^a FUDAN UNIVERSITY   (China)

^b Kanglian Hospital   (China)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA; COMPLEMENTARY DNA; MUTANT PROTEIN;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; EXPRESSION VECTOR; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MUTAGENESIS; PHENOTYPE; SIGNAL TRANSDUCTION; UPREGULATION; AMINO ACID SUBSTITUTION; CANCER INVASION; CELL MOTION; ENDOMETRIUM TUMOR; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; CELL MOVEMENT; DNA, COMPLEMENTARY; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; MUTANT PROTEINS; MUTATION; NEOPLASM INVASIVENESS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71049146802     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-103     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30. 10.3322/canjclin.55.1.10, 15661684.
2. Parazzini F, Lavecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1998, 41:1-16.
3. Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol 2001, 83:485-490. 10.1006/gyno.2001.6429, 11733960.
4. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908. 10.1038/sj.onc.1208615, 15838523.
5. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338. 10.1038/sj.onc.1207396, 14743206.
6. Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis 2007, 24:471-483. 10.1007/s10585-007-9084-8, 17636407.
7. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814. 10.1038/nm0796-811, 8673929.
8. Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Roop DR. Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog 1998, 23:185-192. 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5, 9833779.
9. Müller BF, Paulsen D, Deppert W. Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene 1996, 12:1941-1952.
10. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994, 145:702-714.
11. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485. 10.1038/sj.onc.1202314, 9927204.
12. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009, 16:8-13.
13. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 1991, 51:6506-6509.
14. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553. 10.1126/science.1068999, 11910072.
15. Oleinik NV, Krupenko NI, Priest DG, Krupenko SA. Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J 2005, 391:503-511. 10.1042/BJ20050533, 1276951, 16014005.
16. Hamada J, Omatsu T, Okada F, Furuuchi K, Okubo Y, Takahashi Y, Tada M, Miyazaki YJ, Taniguchi Y, Shirato H, Miyasaka K, Moriuchi T. Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int J Cancer 2001, 93:516-525. 10.1002/ijc.1357, 11477555.
17. Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 2001, 93:773-780. 10.1002/ijc.1413, 11519036.
18. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor - positive tumors. A new paradigm for cancer therapy. American Cancer Society 2002, 94:1593-1611.
19. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16. 10.1016/j.gene.2005.10.018, 16377102.
20. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994, 53:84-92. 10.1006/gyno.1994.1092, 7909788.
21. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996, 16:6009-6019. 231603, 8887630.
22. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 2009, 106:1113-1122. 10.1002/jcb.22098, 19229860.
23. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006, 29:269-278.
24. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25:304-309.
25. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nat Genet 1993, 4:42-46. 10.1038/ng0593-42, 8099841.
26. Jones MW, Kounelis S, Hsu C, Papadaki H, Bakker A, Swalsky PA, Finkelstein SD. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol 1997, 16:354-360.
27. Hsiao M, Low J, Dorn E, Ku D, Pattenganle P, Yeargin J, Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994, 145:702-714. 1890319, 8080050.
28. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37:9-15. 10.1016/S0959-8049(01)00231-3, 11165124.
29. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 1994, 73:370-376. 10.1002/1097-0142(19940115)73:2<370::AID-CNCR2820730222>3.0.CO;2-N, 8293402.
30. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to mutant p53 expression and long-term prognosis. Br J Cancer 1994, 69:1120-1125. 1969432, 7911031.
31. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.